Dry eye syndrome is a clinical condition wherein the patient experiences ocular and conjunctival irritation due to decreased tear production and/or excessive tear evaporation.
It is associated with increased osmolarity of the tear film and inflammation of the ocular surface.
Goal of treatments are to relieve symptoms of patients, to improve visual acuity & quality of life of patients, to restore ocular surface & tear film to normal homeostatic state and to correct the underlying defect.
The patient is advised to follow up, in order to assess their response to therapy, if there is a need to alter or adjust the treatment & to monitor structural ocular damage, as well as to provide reassurance
Frequency & extent of follow-up will depend on the severity of the disease, therapeutic approach & response to therapy
Clinicians should provide their patients w/ proper instructions for their therapeutic regimens, as well as caution them about LASIK, as this may worsen their dry eye condition
May refer their patients to an appropriate specialist, if there are other causes or underlying conditions that would contribute to having dry eye
Patients should be educated about the chronic nature of the disease & its process
Their compliance, understanding of the disease, risks for structural changes should periodically be reassessed
Adding the neuraminidase inhibitor oseltamivir to usual care speeds up recovery from influenza-like illness by a day compared with usual care alone, with even greater benefits seen in older, sicker patients with comorbidities, according to the ALIC4E study.
Anaemia increases mortality risk in heart failure (HF) patients across the ejection fraction (EF) spectrum, a recent study has found. The effect appears to be stronger in preserved (HFpEF) and midrange (HFmrEF) than in reduced (HFrEF) EF disease.